… of tofacitinib in SLE subjects (ClinicalTrials.gov NCT02535689). In this study, 30 subjects
are randomized to tofacitinib (5 mg twice daily) or placebo in 2:1 block. The primary outcome of …

… in this multicentre, double‐blind, vehicle‐controlled trial (NCT01246583). … tofacitinib has
demonstrated efficacy in a 2‐week phase 1 study in psoriasis,9 in a 12‐week phase 2b study in …

… Background Tofacitinib is a novel, oral Janus kinase inhibitor under … Phase 1 multiple‐dose
safety, toleration and pharmacokinetics study demonstrated the efficacy of oral tofacitinib in …

… This Phase 2b study assessed three tofacitinib dosage regimens vs. placebo to characterize
the efficacy and safety of tofacitinib in patients with moderate–to-severe chronic plaque …

… This randomized, double-blind, parallel-group, placebo-controlled … direction of the tofacitinib
research program. The objectives of the study were to characterize the safety and tolerability…

… were to evaluate the safety and efficacy of tofacitinib as an … The second stage was an 8-week
prospective, randomized, … Double-blind, placebo-controlled, dose-escalation study to …

… phase II population described in this analysis consisted of patients from 1 open-label and 8
double-blind… and patients were not randomized to 1 regimen versus the other within any study…

… Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. … phase-III,
multisite, randomized, double-blind clinical studies. Patients were randomized 2:2:1 to tofacitinib 5 …

… A phase I, dose‐escalation study in healthy subjects (ClinicalTrials.gov, NCT01835197) has
been completed. The aim of this study was to evaluate the efficacy, safety … for the study was …

… in one phase IIb study6 and two phase III studies.7 … safety of two oral doses of tofacitinib vs.
placebo during the initial, placebo‐controlled period of 16 weeks in two other global phase III …